Overview

A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at a new chemotherapy schedule in metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Barbara Ann Karmanos Cancer Institute
University of Cincinnati
Collaborators:
Eli Lilly and Company
Genentech, Inc.
Treatments:
Albumin-Bound Paclitaxel
Bevacizumab
Gemcitabine
Paclitaxel